Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was the recipient of unusually large options trading activity on Thursday. Stock traders acquired 27,659 put options on the company. This is an increase of 168% compared to the average volume of 10,336 put options.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s second-quarter revenue of $4.14 billion exceeded analysts’ expectations of $4.02 billion. Management raised its 2026 revenue guidance to $16.5 billion–$16.9 billion, with innovative medicines helping offset weaker generics sales. Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
• Positive Sentiment: UZEDY sales reached a record $77 million in the quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue outlook to $270 million–$290 million from $250 million–$280 million, reinforcing the company’s branded-drug growth strategy. UZEDY Record Q2 Net Sales and Raised Outlook
• Positive Sentiment: Teva said its three key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in quarterly revenue. The company raised its 2026 outlook for AUSTEDO, AJOVY and UZEDY, supporting optimism about its pivot toward higher-growth branded medicines. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: Analyst confidence also provided support, with Piper Sandler forecasting substantial potential appreciation for TEVA shares. Teva’s pipeline and regulatory progress on additional long-acting treatments may strengthen its longer-term growth case. Piper Sandler Forecasts Strong Price Appreciation
• Neutral Sentiment: Trading activity was unusually bullish on Wednesday, when investors acquired 23,688 call options, but turned more defensive on Thursday as 27,659 put options changed hands—168% above typical put volume. The activity signals elevated expectations and hedging, but does not establish a clear direction.
• Negative Sentiment: Second-quarter EPS was $0.02, below the $0.08 consensus and sharply below the prior-year result, as Emalex acquisition costs, impairment charges and other expenses weighed on profitability. Teva’s 2026 EPS guidance of $1.91–$2.11 also trails the $2.17 consensus estimate. Teva Quarterly Earnings Report

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TEVA. Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Friday, July 17th. Finally, Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the sale, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. This represents a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 444,673 shares of company stock valued at $15,582,369 in the last quarter. 0.54% of the stock is owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of the business. Victrix Investment Advisors increased its holdings in Teva Pharmaceutical Industries by 9.5% in the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock worth $266,000 after buying an additional 681 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Teva Pharmaceutical Industries by 128.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock worth $103,538,000 after buying an additional 1,716,315 shares during the last quarter. GAMMA Investing LLC lifted its stake in Teva Pharmaceutical Industries by 19.6% during the 2nd quarter. GAMMA Investing LLC now owns 11,361 shares of the company’s stock valued at $385,000 after acquiring an additional 1,859 shares during the period. Versant Capital Management Inc boosted its holdings in shares of Teva Pharmaceutical Industries by 15.8% during the 2nd quarter. Versant Capital Management Inc now owns 10,265 shares of the company’s stock valued at $348,000 after acquiring an additional 1,399 shares during the last quarter. Finally, CX Institutional purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $54,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Up 2.1%

Shares of TEVA traded up $0.74 on Thursday, hitting $35.45. 8,765,375 shares of the stock traded hands, compared to its average volume of 7,324,332. Teva Pharmaceutical Industries has a one year low of $14.99 and a one year high of $37.35. The company has a market capitalization of $40.76 billion, a PE ratio of 26.65, a P/E/G ratio of 3.35 and a beta of 0.86. The business has a 50 day simple moving average of $33.19 and a 200 day simple moving average of $32.69. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $4.14 billion for the quarter. As a group, equities analysts forecast that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.